NLS Camurus

Biotech Business - June 25, 2020

Camurus announces stronger than expected sales during the first half of 2020

Camurus  has announced revised full year 2020 guidance for the company’s revenue and product sales. Camurus’ guidance for net revenue is increased to SEK 340–380 million from SEK 290–330 million with estimated product sales of SEK 310–340 million, previously SEK 240–280 million. The improvements are driven by increasing market shares of Buvidal for treatment of […]

Drug Development Pharma - October 2, 2017

EMA Validation for Camurus

The company’s marketing authorization application (MAA) for the investigational, weekly and monthly CAM2038 buprenorphine depots for the treatment of opioid dependence has been fully validated by the European Medicines Agency. The application, submitted on 26 July 2017, is now under assessment by the Committee for Human Medicinal Products (CHMP). “The validation of the MAA for CAM2038 […]

Clinical Trials - August 7, 2017

Camurus and Braeburn Pharmaceuticals announces Phase 2 results

Braeburn Pharmaceuticals and Camurus has announced positive results from a Phase 2 pharmacokinetic study of weekly and monthly buprenorphine (CAM2038) depots in opioid dependent patients with moderate-to-severe non-cancer chronic pain. A total of 65 participants were enrolled and received one of three doses of CAM2038 after being transitioned from sublingual buprenorphine. The primary study objective […]

Clinical Trials - May 2, 2017

Camurus announces positive clinical trial results

Braeburn Pharmaceuticals and Camurus announces positive top-line results from a long-term Phase 3 trial supporting the safety and efficacy of CAM2038 in patients with moderate-to-severe opioid use disorder. “The positive results from this study, coupled with the earlier reported positive results from the pivotal Phase 3 efficacy trial, enable our teams to finalize regulatory submissions […]

Collaboration - February 8, 2017

Two new Swedish industry research centres with life science focus

The Swedish Foundation for Strategic Research (SSF) is investing 400 million SEK in four industrial research centres, and two of these are focusing on challenges within life science; nucleotide based drugs and personalized diabetes medicine. SSF has decided to establish four industry research centres with the purpose to enable groundbreaking innovation coming from external industrial challenges. […]

Agreement - January 1, 2016

Camurus in agreement with Rhythm

The two companies have entered a license agreement for the use of Camurus’ drug delivery technology, FluidCrystal, to formulate setmelanotide (RM-493), Rhythm’s novel melanocortin-4 receptor (MC4R) agonist. Under the terms of the agreement, Camurus has granted Rhythm a worldwide license to the FluidCrystal technology to formulate setmelanotide and to develop, manufacture, and commercialize this new […]

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.